The Oncology Companion Diagnostic Market was valued at USD 4.12 billion in 2023 and is projected to reach USD 10.60 billion by 2032, growing at a robust CAGR of 11.09% during the forecast period of 2024–2032. This strong expansion reflects the global shift toward precision medicine, where companion diagnostics play a critical role in identifying patient-specific biomarkers and guiding targeted cancer therapies.
Rising cancer incidence across lung, breast, colorectal, and hematological malignancies is significantly increasing demand for biomarker-based diagnostic testing. Companion diagnostics are now central to oncology care, enabling clinicians to select therapies based on genetic and molecular profiles such as EGFR, HER2, BRCA, PD-L1, KRAS, and ALK. In parallel, growing healthcare investments and expanding oncology diagnostic expenditure across government, private, and commercial funding streams are strengthening market adoption worldwide.
Get free Sample Report@ https://www.snsinsider.com/sample-request/5740
Market Dynamics: Precision Medicine Driving Diagnostic Innovation
The accelerating transition toward precision oncology remains the primary growth driver for the oncology companion diagnostic market. Companion diagnostics are increasingly co-developed alongside targeted therapies, ensuring accurate patient stratification and improved clinical outcomes. Regulatory approvals for biomarker-linked therapies and diagnostics, combined with advances in polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies, have significantly enhanced test sensitivity, reliability, and clinical utility.
Strategic collaborations between pharmaceutical companies, diagnostic manufacturers, and research organizations continue to accelerate innovation. These partnerships are enabling faster biomarker validation, streamlined regulatory pathways, and broader clinical adoption. However, despite strong momentum, high test costs, reimbursement variability, and complex regulatory requirements remain key restraints, particularly in cost-sensitive and developing healthcare markets.
Emerging Opportunities and Technological Advancements
Liquid biopsy-based companion diagnostics are emerging as a transformative opportunity for the market. These non-invasive tests allow real-time tumor monitoring and mutation detection, reducing reliance on traditional tissue biopsies. Additionally, the integration of artificial intelligence (AI) and advanced bioinformatics into genomic analysis is improving interpretation accuracy and turnaround times, making companion diagnostics more scalable across clinical settings.
NGS-based multi-gene panel testing is further reshaping oncology diagnostics by enabling comprehensive genomic profiling in a single assay. As sequencing costs decline and clinical guidelines increasingly recommend broad molecular testing, adoption of advanced companion diagnostics is expected to accelerate significantly through 2032.
Segmentation Insights Highlight Strong Product and Technology Demand
By product and services, the product segment dominated the market in 2023, accounting for 67.3% of total revenue, driven by widespread adoption of assay kits, reagents, and biomarker-based test kits essential for targeted oncology therapies. Meanwhile, diagnostic services are anticipated to register the fastest growth as demand rises for laboratory-developed tests and outsourced molecular testing.
From a technology perspective, PCR-based diagnostics led the market with a 23.3% share in 2023, owing to their cost-effectiveness, sensitivity, and rapid turnaround. However, NGS technology is expected to witness the highest growth rate during the forecast period due to its ability to analyze multiple actionable mutations simultaneously.
Disease Type and End-Use Trends
Non-Small Cell Lung Cancer (NSCLC) held the largest disease-type share in 2023, representing 31.3% of the market, supported by extensive biomarker testing requirements and targeted therapy approvals. Breast cancer is projected to be the fastest-growing segment, fueled by increased genetic screening and HER2- and BRCA-focused diagnostics.
By end-use, hospitals accounted for 52.8% of market revenue in 2023, reflecting their advanced diagnostic infrastructure and integrated oncology services. Pathology and diagnostic laboratories are expected to grow rapidly as high-throughput molecular testing and outsourced diagnostics gain traction.
Regional Outlook: Asia-Pacific Poised for Fastest Growth
North America dominated the oncology companion diagnostic market in 2023, supported by advanced healthcare infrastructure, favorable reimbursement policies, and strong regulatory backing. Europe followed closely, driven by government-supported precision medicine initiatives and rising molecular diagnostic adoption.
The Asia-Pacific region is forecast to register the fastest growth rate through 2032, propelled by increasing cancer prevalence, expanding access to healthcare, growing genomic research investments, and rising awareness of personalized oncology treatments across China, Japan, and India.
Other Trending Reports
Nicotine Replacement Therapy Market
Predictive Genetic Testing & Consumer/Wellness Genomics Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
